Collegium Shares Slide After Q2 Results and Lowered Revenue Outlook
Collegium Pharmaceutical's stock plunged in pre-market trading after the company reported second-quarter 2026 results and narrowed its full-year revenue outlook. While adjusted EPS and adjusted EBITDA beat consensus, revenue slightly missed analyst expectations and the updated guidance midpoint was below prior Street estimates, prompting investor s…